Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on November 17, 2020. The company, incorporated in Delaware and trading on The Nasdaq Stock Market under the symbol KROS, is an emerging growth company. The report specifically addresses the closing of a previously announced public offering of common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As this is a Current Report regarding a corporate event rather than a periodic financial report (10-K or 10-Q), detailed financial statements are not included in this document.
Material Changes
- Capital Raise: The company announced the closing of its public offering of common stock on November 17, 2020.
- Reference: Details regarding the offering are contained in the press release attached as Exhibit 99.1, which is incorporated by reference.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the offering closing. Investors are directed to the attached press release (Exhibit 99.1) for further details on the transaction.
Investor Verification Checklist
- Verify the total number of shares sold and the price per share in the attached press release (Exhibit 99.1).
- Confirm the total gross proceeds raised from the offering.
- Review the use of proceeds disclosed in the offering documents.
- Check for any underwriting discounts or commissions associated with the offering.